JP2018513138A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513138A5
JP2018513138A5 JP2017550832A JP2017550832A JP2018513138A5 JP 2018513138 A5 JP2018513138 A5 JP 2018513138A5 JP 2017550832 A JP2017550832 A JP 2017550832A JP 2017550832 A JP2017550832 A JP 2017550832A JP 2018513138 A5 JP2018513138 A5 JP 2018513138A5
Authority
JP
Japan
Prior art keywords
dosage form
weight
polyethylene glycol
polyvinyl alcohol
russia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017550832A
Other languages
English (en)
Japanese (ja)
Other versions
JP6713483B2 (ja
JP2018513138A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/025176 external-priority patent/WO2016161069A1/en
Publication of JP2018513138A publication Critical patent/JP2018513138A/ja
Publication of JP2018513138A5 publication Critical patent/JP2018513138A5/ja
Application granted granted Critical
Publication of JP6713483B2 publication Critical patent/JP6713483B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017550832A 2015-04-02 2016-03-31 ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形 Active JP6713483B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562141981P 2015-04-02 2015-04-02
US62/141,981 2015-04-02
PCT/US2016/025176 WO2016161069A1 (en) 2015-04-02 2016-03-31 Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020016858A Division JP2020073583A (ja) 2015-04-02 2020-02-04 ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形

Publications (3)

Publication Number Publication Date
JP2018513138A JP2018513138A (ja) 2018-05-24
JP2018513138A5 true JP2018513138A5 (cg-RX-API-DMAC7.html) 2019-03-14
JP6713483B2 JP6713483B2 (ja) 2020-06-24

Family

ID=55806767

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017550832A Active JP6713483B2 (ja) 2015-04-02 2016-03-31 ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形
JP2020016858A Withdrawn JP2020073583A (ja) 2015-04-02 2020-02-04 ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020016858A Withdrawn JP2020073583A (ja) 2015-04-02 2020-02-04 ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形

Country Status (27)

Country Link
US (4) US20160287573A1 (cg-RX-API-DMAC7.html)
EP (1) EP3277278B1 (cg-RX-API-DMAC7.html)
JP (2) JP6713483B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170132325A (cg-RX-API-DMAC7.html)
CN (1) CN107820424B (cg-RX-API-DMAC7.html)
AU (1) AU2016243691A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017021120A2 (cg-RX-API-DMAC7.html)
CA (1) CA2980328A1 (cg-RX-API-DMAC7.html)
CY (1) CY1122828T1 (cg-RX-API-DMAC7.html)
DK (1) DK3277278T3 (cg-RX-API-DMAC7.html)
ES (1) ES2774473T3 (cg-RX-API-DMAC7.html)
HK (1) HK1247105A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20200432T1 (cg-RX-API-DMAC7.html)
HU (1) HUE048785T2 (cg-RX-API-DMAC7.html)
IL (1) IL254593A0 (cg-RX-API-DMAC7.html)
LT (1) LT3277278T (cg-RX-API-DMAC7.html)
ME (1) ME03671B (cg-RX-API-DMAC7.html)
MX (1) MX2017012474A (cg-RX-API-DMAC7.html)
PH (1) PH12017501767A1 (cg-RX-API-DMAC7.html)
PL (1) PL3277278T3 (cg-RX-API-DMAC7.html)
PT (1) PT3277278T (cg-RX-API-DMAC7.html)
RS (1) RS60074B1 (cg-RX-API-DMAC7.html)
RU (1) RU2017134794A (cg-RX-API-DMAC7.html)
SI (1) SI3277278T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000157T1 (cg-RX-API-DMAC7.html)
TW (1) TW201642856A (cg-RX-API-DMAC7.html)
WO (1) WO2016161069A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160287573A1 (en) 2015-04-02 2016-10-06 Theravance Biopharma R&D Ip, Llc Combination dosage form of a mu opioid receptor antagonist and an opioid agent
EP3666261B1 (en) * 2017-08-08 2025-01-15 Mitsubishi Chemical Corporation Pharmaceutical tablet and method for producing same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226730B1 (en) 1997-12-22 2009-08-28 Euro Celtique Sa Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrextone
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
US7914818B2 (en) * 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
EP1572164A2 (en) * 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
AU2004314693B2 (en) 2003-09-26 2011-04-07 Alza Corporation Drug coating providing high drug loading and methods for providing the same
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
JP5042043B2 (ja) * 2005-03-02 2012-10-03 セラヴァンス, インコーポレーテッド 5−ht4レセプターアゴニストであるキノリン化合物
ES2366058T3 (es) * 2006-03-01 2011-10-14 Theravance, Inc. Compuestos de 8-azabiciclo[3.2.1]octano como antagonistas de los receptores opioides mu.
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
CN101500542A (zh) * 2006-07-11 2009-08-05 共有药物有限公司 控释制剂
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc 8-氮雜雙環〔3.2.1〕辛烷化合物之結晶型
TWI415850B (zh) 2007-07-20 2013-11-21 Theravance Inc 製備mu類鴉片受體拮抗劑之中間物的方法
DK2294012T3 (da) * 2008-05-07 2014-10-06 Salix Pharmaceuticals Ltd Administration af et tarmrensemiddel og et antibiotika til behandlingen af tarmsygdom
EP2210595A1 (en) 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms
WO2010132204A1 (en) * 2009-05-12 2010-11-18 Bpsi Holdings, Llc. Enhanced moisture barrier immediate release film coating systems and substrates coated therewith
IT1398930B1 (it) * 2010-03-24 2013-03-28 Molteni & C Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
AU2011295837B2 (en) * 2010-09-03 2015-06-18 Astrazeneca Uk Limited Drug formulations using water soluble antioxidants
WO2012106303A1 (en) 2011-02-01 2012-08-09 Bristol-Myers Squibb Company Pharmaceutical formulations including an amine compound
US9339489B2 (en) * 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
US20160287573A1 (en) 2015-04-02 2016-10-06 Theravance Biopharma R&D Ip, Llc Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Similar Documents

Publication Publication Date Title
JP2008280351A5 (cg-RX-API-DMAC7.html)
CA2561109A1 (en) Gastric retention system
JPS61176521A (ja) 投与形態物の処理方法
JP2010510260A5 (cg-RX-API-DMAC7.html)
FI3562486T3 (fi) Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa
BR112016001822B1 (pt) Comprimido farmacêutico compreendendo ácido acetilsalicílico e clopidogrel e seu processo de fabricação
JP2018514523A5 (cg-RX-API-DMAC7.html)
JP2014503523A5 (cg-RX-API-DMAC7.html)
JP2016515523A5 (cg-RX-API-DMAC7.html)
RU2013141534A (ru) Составы l-ментола, состоящие из множества частиц, и связанные с ними способы
JP2010540547A5 (cg-RX-API-DMAC7.html)
CN108367078A (zh) 医药微丸的干粉包衣组合物
AR103981A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención
BR112018001859B1 (pt) Comprimido, e, método para produzir um comprimido
HRP20211269T1 (hr) Kompozicije prolijeka na bazi monometil fumarata
CZ2015272A3 (cs) Polymerní film s obsahem fotosensitizérů a jeho použití
WO2012053785A3 (ko) 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
JP2015508411A5 (cg-RX-API-DMAC7.html)
Osei-Yeboah et al. A top coating strategy with highly bonding polymers to enable direct tableting of multiple unit pellet system (MUPS)
JP2018513138A5 (cg-RX-API-DMAC7.html)
Muschert et al. Improved long term stability of aqueous ethylcellulose film coatings: importance of the type of drug and starter core
JP5973170B2 (ja) 固体分子分散物
JP2015120758A5 (cg-RX-API-DMAC7.html)
JP2016033133A5 (cg-RX-API-DMAC7.html)
RU2017134794A (ru) Комбинированная лекарственная форма антагониста мю-опиоидного рецептора и опиоидного средства